Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt | ($82.8M) | ($125.5M) | $22.3M | ($40.0M) | $43.2M | $21.1M | ($322.2M) | ($209.3M) | ($204.2M) | ($402.4M) | ($569.1M) | ($948.4M) | ($1,050.8M) | ($1,180.1M) | ($1,608.5M) | ($1,403.4M) | ($2,184.6M) | ($2,780.6M) | ($3,354.9M) | ($2,294.1M) |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, United Therapeutics Corporation's last 12-month Net Debt is ($2,926.5M), based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, United Therapeutics Corporation's Net Debt growth was (29.2%). The average annual Net Debt growth rates for United Therapeutics Corporation have been 46.5% over the past three years, 38.8% over the past five years.
Over the last year, United Therapeutics Corporation's Net Debt growth was (29.2%), which is lower than industry growth of (0.1%). It indicates that United Therapeutics Corporation's Net Debt growth is Good.